HIV

This guideline provides comprehensive, evidence-based recommendations on prophylaxis, treatment, immunization, and drug interactions for a wide range of pediatric OIs—including new additions for coccidioidomycosis, hepatitis B revaccination, and updated immunization schedules—to guide clinicians caring for HIV‑exposed and infected children.

This guideline offers updated, evidence-based recommendations—from preconception through postpartum—on universal prenatal HIV testing, preferred antiretroviral regimens (e.g., bictegravir/TAF/FTC), maternal viral monitoring, obstetric management, and neonatal prophylaxis to further reduce perinatal HIV transmission toward elimination goals (defined as <1% transmission rate and <1 infection per 100,000 live births).

This information sheet offers an in-depth analysis of current AFP models—including funding mechanisms, stakeholder roles, and implementation strategies—to support sustainability of HIV-related services beyond traditional grant funding. It outlines key considerations and best practices to help health departments and community partners explore and launch innovative financing options for long-term epidemic response planning.

This toolkit supports Ryan White HIV/AIDS Program (RWHAP) Part B AIDS Drug Assistance Programs (ADAPs)—which provide access to HIV-related medications for low-income individuals—in navigating the planning, selection, and implementation of benefits management contracts. It offers key definitions, planning tools, real-world examples, and checklists to help ADAP administrators—new or experienced—align contractor selection with their program’s unique infrastructure and needs.

In this webinar, CDC and HRSA speakers review the calendar year 2027–2031 Integrated HIV Prevention & Care Plan Guidance—highlighting key updates, submission requirements, and real-world recipient examples. The training equips CDC- and HRSA-funded jurisdictions with technical support, planning tools, and strategies to develop coordinated HIV prevention and care efforts by the June 30, 2026 deadline.

This guideline presents a comprehensive state-by-state legal analysis of obligations for healthcare providers and laboratories to report negative HIV test outcomes. It clearly highlights jurisdictional differences, helping public health officials and clinicians ensure compliance with surveillance mandates and improve disease tracking.

GLP-1 receptor agonists (GLP-1s), including semaglutide, tirzepatide, and liraglutide, are increasingly used for weight management and show promise for people living with HIV (PLWH). While these medications are generally safe, PLWH may face additional considerations when using them due to how GLP-1s function and interact with antiretroviral therapy (ART). GLP-1s slow gastric emptying and suppress appetite, which may affect ART absorption; gastrointestinal side effects such as nausea or vomiting may also interfere with consistent ART dosing.

This tool is intended to facilitate the calculation of the number of infections and other health outcomes averted, and the associated savings in direct medical costs and productivity costs, by STI prevention program activities as described in this User Guide and supporting scientific manuscript and appendix. 

This webpage discusses the significant decline in cervical precancers (CIN2+) observed between 2008 and 2022, particularly in women aged 20–24, correlating with HPV vaccination.  

This webpage explores the treatment of Hepatitis C (HCV) and HIV coinfection, addressing the complexities of managing both infections simultaneously. It discusses antiviral treatment options, potential drug interactions, and strategies for monitoring and managing the dual conditions effectively.